Skip To Main Content
Lawrence Eichenfield on Muck Rack

Lawrence Eichenfield

As seen in: Wiley Online Library, JAMA (The Journal of the American Medical Association), HCP Live, Dialnet - Universidad de La Rioja, American Journal of Managed Care, Journal of The American Academy of Dermatology (JAAD), Dermatology Times, Contemporary Pediatrics, Managed Healthcare Executive, Practical Dermatology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lawrence

Contact Lawrence, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tolerability of Roflumilast Cream 0.05% in Children with Eczema, With Lawrence Eichenfield, MD

|
By Lawrence Eichenfield
| consultantlive.com
Lawrence F. Eichenfield, MD, of Rady Children’s Hospital, spoke in another segment of his HCPLive interview on recent long-term safety and tolerability data drawn from the INTEGUMENT-OLE study, reflecting on what roflumilast cream .05% (Zoryve) could be for toddlers and preschoolers with atopic dermatitis.1,2 These findings were poster data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
Open in Who Shared View Duplicates (2) Issue with article?

New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD

|
By Lawrence Eichenfield
| consultantlive.com
Roflumilast cream .05% (Zoryve) has demonstrated meaningful efficacy and a favorable safety profile among infants with mild to moderate atopic dermatitis as young as 3 months, according to new data.1 These phase 2 data were presented during a late-breaking podium session at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, adding new information to the growing body of evidence behind roflumilast cream for infants aged 3 months to less than 24 months with mild to...
Open in Who Shared View Duplicates (2) Issue with article?

Long-Term Safety of Roflumilast Cream for Children, With Lawrence Eichenfield, MD

|
By Lawrence Eichenfield
| consultantlive.com
New long-term INTEGUMENT-OLE open-label extension trial data reinforce roflumilast cream .05% (ZORYVE) as a durable, well-tolerated non-steroidal medication for children aged 2 - 5 years living with atopic dermatitis, with efficacy continuing to build over the full 56-week study period.1,2 In the second half of his discussion with the team at HCPLive, Eichenfield, chief of pediatric and adolescent dermatology at Rady Children's Hospital–San Diego, highlighted what those new results could mean...
Open in Who Shared Issue with article?
See all 30 licensed articles (133 Total)